Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.

Boston Scientific has acquired all remaining shares in its portfolio company Farapulse, having first invested in the University of Iowa spinout in 2014.

Sheng Ye Capital and existing investor So-Young participated in a round for the medical supplies ordering platform sized at a minimum of $70m.

Eli Lilly, Johnson & Johnson and Pfizer helped drug developer TRexBio close its $59m series A round while Slack backed human resources software provider Oyster at a $475m valuation.

SoftBank and Novartis-backed digital therapeutics provider Pear has agreed a reverse merger at a $1.6bn pro forma equity valuation.

Theodorus has contributed to a $23.8m series A round for NeuVasQ, the neurological disease drug developer spun out of Université libre de Bruxelles.

Wake Forest University spinout Renovo closed the round at $6.4m and will put the funding into further development of its brain injury treatment system.

Matrix Partners China and Citic Private Equity Funds Management co-led the series B round, which will fund development of treatments for rare medical conditions.

The Cornell cardiovascular data technology spinout has launched with $54m in funding, $43m coming from an American College of Cardiology-backed series B round.

Lilly Asia Ventures and Baidu Ventures helped the drug discovery software provider push its overall funding past the $310m mark.